Evidence from cohorts of RA, systemic sclerosis, and COVID-19 patients treated with anti-GM-CSF agents indicates a non-trivial incidence of lower respiratory tract infections, including bacterial pneumonia [148] and invasive pulmonary aspergillosis [149]. This evidence concerns the gene CSF2 and rheumatoid arthritis.